Development of mouse tissue transfer model of VEGF gene therapy

VEGF基因治疗小鼠组织移植模型的建立

• 批准号: 15591898
• 负责人: TAKAMATSU Ako
• 金额: $ 2.18万
• 依托单位: Saitama Medical School
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2003
• 资助国家: 日本
• 起止时间: 2003 至 2005
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-15591898/
• 关键词: Plastic surgery; Tissue transfer; Gene therapy; International information exchange

DNA-liposome complex was injected on HR-1 strain mouse (male, body weight 30g) subcutaneously on the groin flap or composite graft on the groin area before or on the operation. 6μg VEGFh165-pBLAST plasmid and Plus. Reagent was diluted with 600μl D-MEM and DNA-liposome complex was made by mixing with 24μl Lipofectin (Invivogen). D-MEM was injected in control group.[experience 1] The increase in microvessel density in the subdermal injected group up to day 3 from was observed.The skin paddle survival on the horizontal extended groin flap in the subdermal injected group was larger than controls(60.0±0.002%% and 48.3±0.19% of total skin paddle respectively). No statistically significant difference was noted between the skin paddle survival in controls and treatments (t=0.67).The skin paddle survival on the composite graft and controls were 18.4±0.12% and 24.7±0.09% of total skin paddle respectively. No statistically significant difference was noted between two groups (t=0.40)[experience 2] Aggregation of inflammatory cell and fibroblast formed capsule layer around the silicone plate in the subdermal injected group. The increase in microvessel density was observed on the surface side of the periphery of the structure. The microvascular findings were also noted above the center of silicone plate.The skin paddle survival on the vertical extended groin flap in the subdermal injected group was 60.0±0.001% of total skin paddle. No statistically significant difference was noted compared with controls (59.6±0.16%)The survival of composite graft treated with VEGF was greater than that of controls(10.3% and 3.4%), but statistical significance was not reached.Any side effect was not observed after VEGF plasmid-liposome complex injection.

将DNA-脂质体复合物注射于HR-1系小鼠（雄性，体重30 g）腹股沟皮瓣或腹股沟区复合移植物皮下。6μg VEGFh 165-pBLAST质粒和Plus.用600μl D-MEM稀释试剂，并通过与24μl Lipofectin（Invivogen）混合制备DNA-脂质体复合物。对照组注射D-MEM。[经验1]皮下注射组的微血管密度从注射后第3天开始增加，皮下注射组水平延伸的腹股沟皮瓣上的皮桨存活率高于对照组（分别占总皮桨的60.0± 0.002%和48.3±0.19%）。对照组和治疗组的皮桨存活率差异无统计学意义（t=0.67），复合移植物和对照组的皮桨存活率分别为18.4±0.12%和24.7±0.09%。两组之间无统计学显著差异（t=0.40）[经验2]皮下注射组中，炎症细胞和成纤维细胞聚集在硅胶板周围形成囊层。在结构的周边的表面侧上观察到微血管密度的增加。硅胶板中心上方也观察到微血管变化，真皮下注射组垂直延伸腹股沟皮瓣的皮桨存活率为总皮桨的60.0±0.001%。VEGF质粒-脂质体复合物注射组移植物存活率（10.3%）高于对照组（3.4%），但无统计学意义，未观察到任何副作用。